StockData

Alumis vs Tvardi Therapeutics

ALMS and TVRD side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ALMS and TVRD compare

Alumis is the larger company, worth 45 times as much as Tvardi Therapeutics ($665M against $14.7M).

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricALMSTVRD
Size and price
Market cap$665M$14.7M
Share price$5.14$1.10
Change, 1 year−2.7%−73.2%
Change, 5 years–−99.8%
Beta (5Y)2.092.71
Employees22412
StockData Score
Total score66
Valuation score11
Growth score00
Performance score00
Health score55
Dividend score00
Valuation
P/S89.9×–
P/B1.5× (better)1.8×
FCF yield−52.9%–
Profitability
Operating margin−6204%–
Net margin−5933%–
FCF margin−4755%–
Return on equity−93.6% (better)−126%
Financial health
Debt / equity0.000.00
Current ratio6.74 (better)1.87
Altman Z-score−0.91 (better)−13.50
Piotroski F-score2 (better)1
Dividends and buybacks
Dividend yield–0.00%
Years of dividend growth–0
Shareholder yield0.00%0.00%
Ownership
Held by institutions91.3%16.7%
Held by insiders30.5%15.6%
Insider net buying, 12 months$44.7M–
Short interest, % of float12.3%2.7%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.